Shanghai Rightongene Biotechnology Co., Ltd. (SHA:688217)
China
· Delayed Price · Currency is CNY 23.63
-0.37 (-1.54%)
At close: Jun 5, 2025, 2:57 PM CST
SHA:688217 Revenue
Shanghai Rightongene Biotechnology had revenue of 54.74M CNY in the quarter ending March 31, 2025, a decrease of -14.72%. This brings the company's revenue in the last twelve months to 232.86M, down -12.30% year-over-year. In the year 2024, Shanghai Rightongene Biotechnology had annual revenue of 242.31M, down -6.16%.
Revenue (ttm)
232.86M
Revenue Growth
-12.30%
P/S Ratio
5.67
Revenue / Employee
580.69K
Employees
401
Market Cap
1.32B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 29.19B |
| Shenzhen Mindray Bio-Medical Electronics | 35.59B |
| WuXi AppTec | 39.59B |
| Sichuan Biokin Pharmaceutical | 5.82B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
| Aier Eye Hospital Group | 21.81B |
| Shanghai United Imaging Healthcare | 10.43B |
| Yunnan Baiyao Group Co.,Ltd | 40.10B |